A new study found that adults with alcohol use disorder (AUD) who started treatment with GLP-1 receptor agonists like semaglutide and tirzepatide had significantly fewer alcohol-related hospitalizations compared to those on other diabetes or obesity medications. The study analyzed health records of over 40,000 adults with AUD and either type 2 diabetes or obesity, showing a 22-32% reduction in hospitalization risk. Researchers used advanced methods to mimic randomized trials but caution that further clinical trials are needed to confirm causality. These findings suggest GLP-1 receptor agonists could play a role in reducing alcohol-related harm, highlighting a potential new avenue for treatment.
Meta has agreed to an $18 billion legal settlement, which translates to about $1 billion per year—an amount negligible compared to its substantial revenue and earnings. The settlement resolves regulatory uncertainties, allowing Meta to focus on its c...
Genius Group, after selling its entire Bitcoin reserve to repay $8.5 million in debt, plans to rebuild its Bitcoin and AI treasuries to a combined $1.6 billion by fiscal year 2031. The company aims to grow total assets to $2 billion and will fund tre...
Veteran trader Peter Brandt revealed he remains long on Bitcoin even as the cryptocurrency struggles to break above the key resistance zone around $82,000. Bitcoin recently climbed above $80,000 but faced strong selling pressure, causing a pullback. ...
Grayscale's Zach Pandl highlights that the US Treasury's bond repurchases aim to ease pressure from soaring government debt, which recently surpassed $40 trillion. While these repurchases may reduce Treasury supply and stimulate the economy, they don...
GoMining introduced Instant Funds, a feature enabling eligible digital Bitcoin miner NFT holders to use their miners as collateral to borrow stablecoins like USDT or USDC without selling the miners. Users can access up to 30% of the miner's value wit...
